Anti-Infective Antibacterial Agents against Mycobacterium Tuberculosis and other Mycobacterium Species


Project ID: D2016-53


IP Status: PCT patent application #PCT/US17/028782


Invention Description and Novelty: New compound represents useful antimicrobial agents effective against human and veterinary pathogens, particularly acid-fast organisms such as Mycobacterium tuberculosis and shows improved efficacy and activity well below toxicity to human monocytic cells.


Background: Mycobacterium tuberculosis (Mtb) is an acid-fast gram-positive bacillus that causes tuberculosis (TB). TB ranks first for the number of deaths in humans caused by an infectious agent. In 2013 there were 9.0 million active cases of TB. It is notable that the number of multi drug-resistant TB (MDR-TB) cases tripled from 2009 to 2013. This increase in MDR-TB and extensively drug-resistant TB (XDR-TB) has drawn worldwide attention. Furthermore, HIV-TB co-infection is a serious problem in countries where TB is endemic. HIV positive patients are 26-31 times more likely to develop active TB in comparison to an HIV negative person. Overall, 1.5 million people die every year from this disease.


Applications: Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium avium and other species


Value proposition:

•       In some embodiments, the compounds are active at concentrations 20-fold lower than toxicity, are active against the most important drug-resistant strains of Mtb and mycobacteria other than Mtb, and may be effective against many different types of organisms other than Mycobacteria species

•       Compound showed an impressive potency (MIC = 0.20-0.44 μM) against Mtb strains resistant to isoniazid, rifampicin and fluoroquinolones, suggesting activity against MDR and XDR strains of Mtb.

•       Includes methods for making compounds as well as kits for making derivatives.

•       Activity in certain Mtb infected cells indicates that physical properties may be further improved.


Patent Information:
For Information, Contact:
Katherine Pollard
Licensing Associate
The University of Toledo
Steven Sucheck
Sandeep Thanna
Slayden Richard
Extensively drug-resistant TB
Multi-drug resistant TB
Mycobacterium abscessus
Mycobacterium tuberculosis